

# Five Things to Know About Vaccine Economics

David Bishai, MD, MPH, PhD

Clinical Professor and Director

The University of Hong Kong School of Public Health


# Outline

1. Private markets can't finance vaccines sufficiently
2. Private demand won't allocate vaccines fairly
3. Reaching the last 20% will cost more
4. Returns to scale in production so big plants make lower cost vaccines
5. Better forecasts of demand can lower costs

# Private Demand

- Private demand is a choice
- Individual perception that  $\text{benefit} > \text{cost}$
- Demand is for lower  $Q$  when prices are higher
- Buy vaccine if maximal willingness to pay  $> P$

Price




$Q^*$

Quantity

# Demand Curve

- Based on perceived Value of  $\downarrow$ Risk in Vaccinee
- Vaccinee does not consider benefit to others
  - Private demand too low to reach herd immunity
- Society subsidizes to offer  $P=free$



# Shifting a Demand Curve

Sometimes even free vaccines do not produce enough demand


Shift right

Marketing

Information

Tribal affiliations


Price



# Private Market is Not Fair

- Demand
  - Purchase Q-High price  $P^*$
  - High incomes mean disease costs more to them
    - More expensive medical bills
    - Higher lost wages


Price



# Private Market is Not Fair

- Low Income Country Purchases Less
- Implications when a high income country and low income country are neighbors?

Price



# The Intransigent Last 20%

Demand Curves Actually Not Linear

First 80% or so respond to incentives

The holdouts are increasingly expensive/impossible to convert

- Religious beliefs

- Existential core antivax identity

- Live in deepest forest


- Live on highest mountain

Outreach costs

Small session costs


Must be prepared to pay these costs

Price





# Returns to Scale in Production



# Why Declining Returns?

- Vaccine production has large fixed costs
  - Big factories
  - Training up the capability of the workforce on each product
  - Distribution networks for each product line
  - Licensed intellectual property
- Once the fixed costs are spent
  - Marginal cost of first vial  $\gg$  Marginal cost of millionth vial

# Vaccine Forecasts Can Lower Costs

- It costs money to borrow capita to finance the fixed costs
- Borrowing too much money means wasteful interest payments
- Some vaccines take 6-12 months to produce
  - Raw materials are purchased up front
  - Plants could be producing other high value products
  - A canceled order means large losses
  - Can put the risk of a cancelled order into the pricing
- Investors will lend money at lower rates if they see certainty around future market size projections

# Summary

1. Private markets can't finance vaccines sufficiently
2. Private demand won't allocate vaccines fairly
3. Reaching the last 20% will cost more
4. Returns to scale in production
5. Better forecasts of demand can lower costs